Focusing on innovation and patient accessibility, we have established a diversified and complementary R&D pipeline. Most products are independently developed through our own platform, and we have a number of potential novel antitumor targets drugs. Our products respond to a vast array of diseases, including cancer, autoimmune, metabolic, neurological, and infectious diseases. As we continue … Continue reading R&D Pipeline